Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?
{{output}}
This Practice Point commentary discusses the findings of the first phase I trial to evaluate abiraterone acetate (an inhibitor of the androgen-regulating enzyme CYP17) in the treatment of castration-resistant prostate cancer. This open-label, dose-escalation s... ...
